101 related articles for article (PubMed ID: 26460795)
1. A Phase I Study of the Hsp90 Inhibitor AUY922 plus Capecitabine for the Treatment of Patients with Advanced Solid Tumors.
Bendell JC; Jones SF; Hart L; Pant S; Moyhuddin A; Lane CM; Earwood C; Murphy P; Patton J; Penley WC; Thompson D; Infante JR
Cancer Invest; 2015; 33(10):477-82. PubMed ID: 26460795
[TBL] [Abstract][Full Text] [Related]
2. Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma.
Seggewiss-Bernhardt R; Bargou RC; Goh YT; Stewart AK; Spencer A; Alegre A; Bladé J; Ottmann OG; Fernandez-Ibarra C; Lu H; Pain S; Akimov M; Iyer SP
Cancer; 2015 Jul; 121(13):2185-92. PubMed ID: 25809731
[TBL] [Abstract][Full Text] [Related]
3. A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal Tumors.
Bendell JC; Bauer TM; Lamar R; Joseph M; Penley W; Thompson DS; Spigel DR; Owera R; Lane CM; Earwood C; Burris HA
Cancer Invest; 2016 Jul; 34(6):265-70. PubMed ID: 27379708
[TBL] [Abstract][Full Text] [Related]
4. Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors.
Doi T; Onozawa Y; Fuse N; Yoshino T; Yamazaki K; Watanabe J; Akimov M; Robson M; Boku N; Ohtsu A
Cancer Chemother Pharmacol; 2014 Sep; 74(3):629-36. PubMed ID: 25059319
[TBL] [Abstract][Full Text] [Related]
5. First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors.
Sessa C; Shapiro GI; Bhalla KN; Britten C; Jacks KS; Mita M; Papadimitrakopoulou V; Pluard T; Samuel TA; Akimov M; Quadt C; Fernandez-Ibarra C; Lu H; Bailey S; Chica S; Banerji U
Clin Cancer Res; 2013 Jul; 19(13):3671-80. PubMed ID: 23757357
[TBL] [Abstract][Full Text] [Related]
6. Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen.
Kong A; Rea D; Ahmed S; Beck JT; López López R; Biganzoli L; Armstrong AC; Aglietta M; Alba E; Campone M; Hsu Schmitz SF; Lefebvre C; Akimov M; Lee SC
Oncotarget; 2016 Jun; 7(25):37680-37692. PubMed ID: 27129177
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer.
Renouf DJ; Hedley D; Krzyzanowska MK; Schmuck M; Wang L; Moore MJ
Cancer Chemother Pharmacol; 2016 Sep; 78(3):541-5. PubMed ID: 27422303
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of heat shock protein 90 with AUY922 represses tumor growth in a transgenic mouse model of islet cell neoplasms.
Fendrich V; Wichmann S; Wiese D; Waldmann J; Lauth M; Rexin P; L-Lopez C; Schlitt HJ; Bartsch DK; Lang SA
Neuroendocrinology; 2014; 100(4):300-9. PubMed ID: 25301256
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Johnson ML; Yu HA; Hart EM; Weitner BB; Rademaker AW; Patel JD; Kris MG; Riely GJ
J Clin Oncol; 2015 May; 33(15):1666-73. PubMed ID: 25870087
[TBL] [Abstract][Full Text] [Related]
10. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
Walsby EJ; Lazenby M; Pepper CJ; Knapper S; Burnett AK
Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies.
Saif MW; Lansigan F; Ruta S; Lamb L; Mezes M; Elligers K; Grant N; Jiang ZL; Liu SH; Cheng YC
Phytomedicine; 2010 Mar; 17(3-4):161-9. PubMed ID: 20092990
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma.
Gaspar N; Sharp SY; Eccles SA; Gowan S; Popov S; Jones C; Pearson A; Vassal G; Workman P
Mol Cancer Ther; 2010 May; 9(5):1219-33. PubMed ID: 20457619
[TBL] [Abstract][Full Text] [Related]
13. Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma.
Augello G; Emma MR; Cusimano A; Azzolina A; Mongiovì S; Puleio R; Cassata G; Gulino A; Belmonte B; Gramignoli R; Strom SC; McCubrey JA; Montalto G; Cervello M
Int J Cancer; 2019 May; 144(10):2613-2624. PubMed ID: 30488605
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Study of AUY922, a Novel Hsp90 Inhibitor, in the Treatment of Esophageal Adenocarcinoma.
Kosovec JE; Zaidi AH; Kelly LA; Rotoloni CL; Vytlacil C; DiCarlo C; Matsui D; Komatsu Y; Boyd NH; Omstead A; Kolano EL; Biederman RW; Finley G; Silverman JF; Landreneau RJ; Jobe BA
Ann Surg; 2016 Aug; 264(2):297-304. PubMed ID: 26445473
[TBL] [Abstract][Full Text] [Related]
15. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.
Nagengast WB; de Korte MA; Oude Munnink TH; Timmer-Bosscha H; den Dunnen WF; Hollema H; de Jong JR; Jensen MR; Quadt C; Garcia-Echeverria C; van Dongen GA; Lub-de Hooge MN; Schröder CP; de Vries EG
J Nucl Med; 2010 May; 51(5):761-7. PubMed ID: 20395337
[TBL] [Abstract][Full Text] [Related]
16. HSP90 inhibitor NVP-AUY922 induces cell apoptosis by disruption of the survivin in papillary thyroid carcinoma cells.
Liu J; Sun W; Dong W; Wang Z; Qin Y; Zhang T; Zhang H
Biochem Biophys Res Commun; 2017 May; 487(2):313-319. PubMed ID: 28412368
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer.
Felip E; Barlesi F; Besse B; Chu Q; Gandhi L; Kim SW; Carcereny E; Sequist LV; Brunsvig P; Chouaid C; Smit EF; Groen HJM; Kim DW; Park K; Avsar E; Szpakowski S; Akimov M; Garon EB
J Thorac Oncol; 2018 Apr; 13(4):576-584. PubMed ID: 29247830
[TBL] [Abstract][Full Text] [Related]
18. Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma.
Kaiser M; Lamottke B; Mieth M; Jensen MR; Quadt C; Garcia-Echeverria C; Atadja P; Heider U; von Metzler I; Türkmen S; Sezer O
Eur J Haematol; 2010 Apr; 84(4):337-44. PubMed ID: 20028416
[TBL] [Abstract][Full Text] [Related]
19. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis.
Eccles SA; Massey A; Raynaud FI; Sharp SY; Box G; Valenti M; Patterson L; de Haven Brandon A; Gowan S; Boxall F; Aherne W; Rowlands M; Hayes A; Martins V; Urban F; Boxall K; Prodromou C; Pearl L; James K; Matthews TP; Cheung KM; Kalusa A; Jones K; McDonald E; Barril X; Brough PA; Cansfield JE; Dymock B; Drysdale MJ; Finch H; Howes R; Hubbard RE; Surgenor A; Webb P; Wood M; Wright L; Workman P
Cancer Res; 2008 Apr; 68(8):2850-60. PubMed ID: 18413753
[TBL] [Abstract][Full Text] [Related]
20. 2-phenylethynesulphonamide (PFT-μ) enhances the anticancer effect of the novel hsp90 inhibitor NVP-AUY922 in melanoma, by reducing GSH levels.
Yeramian A; Vea A; Benítez S; Ribera J; Domingo M; Santacana M; Martinez M; Maiques O; Valls J; Dolcet X; Vilella R; Cabiscol E; Matias-Guiu X; Marti RM
Pigment Cell Melanoma Res; 2016 May; 29(3):352-71. PubMed ID: 26988132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
